Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 30.00 |
|---|---|
| High | 32.60 |
| Low | 30.00 |
| Bid | 31.00 |
| Offer | 31.80 |
| Previous close | 29.80 |
| Average volume | 0.00 |
|---|---|
| Shares outstanding | 57.12m |
| Free float | 54.80m |
| P/E (TTM) | 55.17 |
| Market cap | 2.08bn USD |
| EPS (TTM) | 0.66 USD |
Data delayed at least 15 minutes, as of Mar 02 2026 18:30 GMT.
More ▼
Press releases
- Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
- Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
- Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA)
- Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
- Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
- Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome
- Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
- Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
- Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
More ▼
